should patients with tp53-mutated mds receive stem cell transplant?
Published 9 months ago • 815 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:27
treatment options for patients with tp53-mutated aml
-
3:56
treatment approaches for patients with tp53-mutated mcl
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
7:37
magrolimab in tp53-mutated aml and mds: what are the latest updates from eha2022?
-
6:49
phase iii trial of intensification and consolidation therapy in newly diagnosed myeloma
-
10:05
multiple myeloma transplant: examining the intersection of access, age and race
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
1:27
tp53-aberrant mcl: challenges and treatment approaches
-
2:16
the potential use of proteomics for predicting relapse in patients with mds undergoing allosct
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
2:31
stem cell collection in patients with multiple myeloma treated with anti-cd38 monoclonal antibodies
-
1:04
continuous treatment with flt3 inhibitors for patients with flt3-mutated aml undergoing allosct
-
3:37
implementing pharmacogenomics-driven supportive care for stem cell transplant recipients
-
2:15
is the collection of backup stem cells necessary?
-
0:59
the treatment of patients with t(11;14) myeloma
-
2:41
an overview of the latest advances in hematology